The first made in China coronavirus vaccine based on a recombinant protein platform has been jointly developed by the Institute of Microbiology and Anhui Zhifei Longcam biotech, a subsidiary of Chongqing Zhifei Biological Products Co. Ltd.
A filing by the Shenzhen-listed company shows that the vaccine is now under Phase III development and on the cusp of being registered in the Central Asian country of Uzbekistan, where a study conducted in December reportedly